481 A CXCR4 partial agonist TFF2-MSA sensitized advanced gastric cancer to PD-1 blockade by systematically reducing PMN-MDSC accumulation, immunosuppression, and generation in bone marrow
BackgroundPolymorphonuclear myeloid-derived suppressor cell (PMN-MDSC) is pathologically activated immature neutrophil that exerts immunosuppressive functions. PMN-MDSC is short-lived and constantly replenished through bone marrow (BM) myelopoiesis. Within the BM, histidine decarboxylase (HDC) expre...
Saved in:
Published in | Journal for immunotherapy of cancer Vol. 11; no. Suppl 1; p. A540 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
London
BMJ Publishing Group Ltd
01.11.2023
BMJ Publishing Group LTD BMJ Publishing Group |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | BackgroundPolymorphonuclear myeloid-derived suppressor cell (PMN-MDSC) is pathologically activated immature neutrophil that exerts immunosuppressive functions. PMN-MDSC is short-lived and constantly replenished through bone marrow (BM) myelopoiesis. Within the BM, histidine decarboxylase (HDC) expressing immature neutrophil constitute a histaminergic niche that enforces hematopoietic stem cell quiescence and inhibits pathological myelopoiesis.1 Trefoil factor family 2 (TFF2), a partial agonist for CXCR4, inhibits CXCL12-dependent chemotaxis.2 Here we engineered a stabilized TFF2 peptide linked to mouse serum albumin (TFF2-MSA), and investigated its effect on PMN-MDSC and combination with PD1 inhibitor in advanced gastric cancer mouse models.MethodsA syngeneic gastric cancer cell line ACKP (Atp4b-Cre; Cdh1-/-; LSL-KrasG12D; Trp53-/-) was grafted subcutaneously into HDC-GFP transgenic mice to trace HDC-GFP+MDSCs. Once tumors reach 200 mm3, mice received TFF2-MSA or/and anti-PD-1 antibody. The CXCR4 antagonist AMD3100 served as comparison to TFF2-MSA. We further established a spontaneous lung metastasis model in which mice bearing ACKP tumors received surgical tumor resection and subsequent TFF2-MSA/anti-PD-1 treatments. In another orthotopic model, ACKP-luciferase cells were implanted to stomach submucosa, and the treatments started after 1 week. At 1 month, flow cytometry and single cell RNA sequencing (scRNA-seq) were performed to study treatment induced immune profile changes.ResultsEither TFF2-MSA or anti-PD-1 monotherapy showed little inhibition of subcutaneous ACKP tumor (15% and 25%, N=10, p>0.05), but their combination dramatically suppressed ACKP growth by 78% in a synergistic manner (p<0.0001). In the lung metastasis model, the combination completely abrogated metastasis in 80% mice (N=10, p<0.0001) and prolonged mice survival (p<0.0001), in contrast to minimal effect of either monotherapy (p>0.05). In the orthotopic model, although either monotherapy only slightly delayed tumor growth, their combination successfully eradicated tumor in 80% mice (N=5, p<0.001). Mechanistically, TFF2-MSA systematically reduced HDC+ PMN-MDSCs in the TME, spleen and blood, and its combination with anti-PD-1 profoundly increased polyfunctional Tim-3-Lag-3-CD8+ T cells in the TME and TCF1+ T cells in the TDLN. Inside BM, TFF2-MSA decreased PMN-MDSC generation from its precursors (MPP3/CMP/GMP/GP) to a level similar to tumor-free mice, and restored hematopoietic stem cell quiescence via histamine feedback loop. Importantly, flow cytometry, scRNA-seq and functional analysis suggested TFF2-MSA treated PMN-MDSCs display a more mature profile with less immunosuppressive property. In contrast, AMD3100 plus anti-PD-1 failed to decrease tumor growth and TME MDSCs possibly due to destruction of BM hematopoietic homeostasis.ConclusionsTFF2-MSA systematically reduced PMN-MDSC, and its immunosuppression and generation in BM, thereby sensitizing advanced gastric cancer to PD-1 inhibitors.ReferencesChen X, Deng H, Churchill MJ, Luchsinger LL, Du X, Chu TH, Friedman RA, Middelhoff M, Ding H, Tailor YH, Wang ALE, Liu H, Niu Z, Wang H, Jiang Z, Renders S, Ho SH, Shah SV, Tishchenko P, Chang W, Swayne TC, Munteanu L, Califano A, Takahashi R, Nagar KK, Renz BW, Worthley DL, Westphalen CB, Hayakawa Y, Asfaha S, Borot F, Lin CS, Snoeck HW, Mukherjee S, Wang TC. Bone Marrow Myeloid Cells Regulate Myeloid-Biased Hematopoietic Stem Cells via a Histamine-Dependent Feedback Loop. Cell Stem Cell. 2017 Dec 7;21(6):747–760.e7.Dubeykovskaya Z, Dubeykovskiy A, Solal-Cohen J, Wang TC. Secreted trefoil factor 2 activates the CXCR4 receptor in epithelial and lymphocytic cancer cell lines. J Biol Chem. 2009 Feb 6;284(6):3650–62.Ethics ApprovalFor experiments in mouse models, all procedures for mice were approved by the Institutional Animal Care and Use Committee of Columbia University in accordance with institutional and NIH guidelines (protocol number AC-AABV0664). |
---|---|
AbstractList | BackgroundPolymorphonuclear myeloid-derived suppressor cell (PMN-MDSC) is pathologically activated immature neutrophil that exerts immunosuppressive functions. PMN-MDSC is short-lived and constantly replenished through bone marrow (BM) myelopoiesis. Within the BM, histidine decarboxylase (HDC) expressing immature neutrophil constitute a histaminergic niche that enforces hematopoietic stem cell quiescence and inhibits pathological myelopoiesis.1 Trefoil factor family 2 (TFF2), a partial agonist for CXCR4, inhibits CXCL12-dependent chemotaxis.2 Here we engineered a stabilized TFF2 peptide linked to mouse serum albumin (TFF2-MSA), and investigated its effect on PMN-MDSC and combination with PD1 inhibitor in advanced gastric cancer mouse models.MethodsA syngeneic gastric cancer cell line ACKP (Atp4b-Cre; Cdh1-/-; LSL-KrasG12D; Trp53-/-) was grafted subcutaneously into HDC-GFP transgenic mice to trace HDC-GFP+MDSCs. Once tumors reach 200 mm3, mice received TFF2-MSA or/and anti-PD-1 antibody. The CXCR4 antagonist AMD3100 served as comparison to TFF2-MSA. We further established a spontaneous lung metastasis model in which mice bearing ACKP tumors received surgical tumor resection and subsequent TFF2-MSA/anti-PD-1 treatments. In another orthotopic model, ACKP-luciferase cells were implanted to stomach submucosa, and the treatments started after 1 week. At 1 month, flow cytometry and single cell RNA sequencing (scRNA-seq) were performed to study treatment induced immune profile changes.ResultsEither TFF2-MSA or anti-PD-1 monotherapy showed little inhibition of subcutaneous ACKP tumor (15% and 25%, N=10, p>0.05), but their combination dramatically suppressed ACKP growth by 78% in a synergistic manner (p<0.0001). In the lung metastasis model, the combination completely abrogated metastasis in 80% mice (N=10, p<0.0001) and prolonged mice survival (p<0.0001), in contrast to minimal effect of either monotherapy (p>0.05). In the orthotopic model, although either monotherapy only slightly delayed tumor growth, their combination successfully eradicated tumor in 80% mice (N=5, p<0.001). Mechanistically, TFF2-MSA systematically reduced HDC+ PMN-MDSCs in the TME, spleen and blood, and its combination with anti-PD-1 profoundly increased polyfunctional Tim-3-Lag-3-CD8+ T cells in the TME and TCF1+ T cells in the TDLN. Inside BM, TFF2-MSA decreased PMN-MDSC generation from its precursors (MPP3/CMP/GMP/GP) to a level similar to tumor-free mice, and restored hematopoietic stem cell quiescence via histamine feedback loop. Importantly, flow cytometry, scRNA-seq and functional analysis suggested TFF2-MSA treated PMN-MDSCs display a more mature profile with less immunosuppressive property. In contrast, AMD3100 plus anti-PD-1 failed to decrease tumor growth and TME MDSCs possibly due to destruction of BM hematopoietic homeostasis.ConclusionsTFF2-MSA systematically reduced PMN-MDSC, and its immunosuppression and generation in BM, thereby sensitizing advanced gastric cancer to PD-1 inhibitors.ReferencesChen X, Deng H, Churchill MJ, Luchsinger LL, Du X, Chu TH, Friedman RA, Middelhoff M, Ding H, Tailor YH, Wang ALE, Liu H, Niu Z, Wang H, Jiang Z, Renders S, Ho SH, Shah SV, Tishchenko P, Chang W, Swayne TC, Munteanu L, Califano A, Takahashi R, Nagar KK, Renz BW, Worthley DL, Westphalen CB, Hayakawa Y, Asfaha S, Borot F, Lin CS, Snoeck HW, Mukherjee S, Wang TC. Bone Marrow Myeloid Cells Regulate Myeloid-Biased Hematopoietic Stem Cells via a Histamine-Dependent Feedback Loop. Cell Stem Cell. 2017 Dec 7;21(6):747–760.e7.Dubeykovskaya Z, Dubeykovskiy A, Solal-Cohen J, Wang TC. Secreted trefoil factor 2 activates the CXCR4 receptor in epithelial and lymphocytic cancer cell lines. J Biol Chem. 2009 Feb 6;284(6):3650–62.Ethics ApprovalFor experiments in mouse models, all procedures for mice were approved by the Institutional Animal Care and Use Committee of Columbia University in accordance with institutional and NIH guidelines (protocol number AC-AABV0664). |
Author | Wang, Timothy C Qian, Jin Lederman, Seth Daugherty, Bruce L Ryeom, Sandra |
Author_xml | – sequence: 1 givenname: Jin surname: Qian fullname: Qian, Jin organization: Columbia University Medical Center, New York, NY, USA – sequence: 2 givenname: Sandra surname: Ryeom fullname: Ryeom, Sandra organization: Columbia University Medical Center, New York, NY, USA – sequence: 3 givenname: Bruce L surname: Daugherty fullname: Daugherty, Bruce L organization: Tonix Pharmaceuticals, Inc, Chatham, NJ, USA – sequence: 4 givenname: Seth surname: Lederman fullname: Lederman, Seth organization: Columbia University Medical Center, New York, NY, USA – sequence: 5 givenname: Timothy C surname: Wang fullname: Wang, Timothy C organization: Columbia University Medical Center, New York, NY, USA |
BookMark | eNpFkc-O0zAQhyMEEsuyz4AlrmTX_5K4xypLodIWVrRI3KyJ7VQOiV3sZFE57YXH4mV4EpwWxMkzo0-_sf29yJ4670yWvSL4mhBW3nR2VDnFlOXb9a6ei2vMBXmSXVBckJxwWj7PrmLsMMYEMyaEuMh-JeL3488lqr_Unzg6QBgt9Aj23tk4ot1qRfPNdomicdGO9ofRCPQDOJWKPcQxWIXU3AY0enR_mxPU9F59BW1Qc0TxGEczwGgV9P0RBaMnZd0e3W8-5JvbbY1AqWmY-kR49wbZYZicj9PhEEyMpxG4tMg4E04Isg416dlogBD895fZsxb6aK7-npfZ59XbXf0-v_v4bl0v7_KGiIrkUHJdqMbwtlHC0BYzszAtMFCNBmyU5goXGjhoynSjC6MVoaoVuFFYLUTFLrP1OVd76OQh2LT-KD1YeRr4sJfzx6neSM4qZkrBBa8UJy0ReFGlVhdatxrrRcp6fc46BP9tMnGUnZ-CS9eXVAheVrQQOFHsTDVD9x8gWM6q5axazoblP9VyVs3-ABPtpRY |
ContentType | Journal Article |
Copyright | Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2023 Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
Copyright_xml | – notice: Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. – notice: 2023 Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
DBID | 9YT ACMMV K9. DOA |
DOI | 10.1136/jitc-2023-SITC2023.0481 |
DatabaseName | BMJ Open Access Journals BMJ Journals:Open Access ProQuest Health & Medical Complete (Alumni) DOAJ Directory of Open Access Journals |
DatabaseTitle | ProQuest Health & Medical Complete (Alumni) |
DatabaseTitleList | ProQuest Health & Medical Complete (Alumni) |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: ACMMV name: BMJ Journals:Open Access url: https://journals.bmj.com/ sourceTypes: Publisher |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2051-1426 |
EndPage | A540 |
ExternalDocumentID | oai_doaj_org_article_4373e684847c41f18097684d5ddfd0d9 jitc |
GroupedDBID | 4.4 53G 5VS 7X7 88E 8FI 8FJ 9YT ABUWG ACGFS ACMMV ADBBV ADRAZ ADUKV AFKRA AHBYD AHSBF AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AOIJS ASPBG AVWKF BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU DIK EBS EJD FYUFA GROUPED_DOAJ H13 HMCUK HYE IAO IHR IHW INH INR ITC KQ8 M1P M48 M~E OK1 PHGZT PIMPY PQQKQ PROAC PSQYO RBZ RMJ ROL RPM RSV SOJ UKHRP K9. PHGZM PJZUB PPXIY PUEGO |
ID | FETCH-LOGICAL-b1871-a64d5cbe4fbc8e2f03e9efa3acbda0ecd4c05da4ad23dbd5edc12cf80bc0c9873 |
IEDL.DBID | M48 |
IngestDate | Wed Aug 27 01:27:31 EDT 2025 Fri Jul 25 21:17:55 EDT 2025 Thu Apr 24 22:49:44 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | Suppl 1 |
Language | English |
License | This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-b1871-a64d5cbe4fbc8e2f03e9efa3acbda0ecd4c05da4ad23dbd5edc12cf80bc0c9873 |
Notes | SITC 38th Annual Meeting (SITC 2023) Abstracts Checkpoint Blockade Therapy ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 |
OpenAccessLink | https://jitc.bmj.com/content/11/Suppl_1/A540.full |
PQID | 2884672580 |
PQPubID | 2040222 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_4373e684847c41f18097684d5ddfd0d9 proquest_journals_2884672580 bmj_journals_10_1136_jitc_2023_SITC2023_0481 |
PublicationCentury | 2000 |
PublicationDate | 20231100 20231101 2023-11-01 |
PublicationDateYYYYMMDD | 2023-11-01 |
PublicationDate_xml | – month: 11 year: 2023 text: 20231100 |
PublicationDecade | 2020 |
PublicationPlace | London |
PublicationPlace_xml | – name: London |
PublicationTitle | Journal for immunotherapy of cancer |
PublicationTitleAbbrev | J Immunother Cancer |
PublicationYear | 2023 |
Publisher | BMJ Publishing Group Ltd BMJ Publishing Group LTD BMJ Publishing Group |
Publisher_xml | – name: BMJ Publishing Group Ltd – name: BMJ Publishing Group LTD – name: BMJ Publishing Group |
SSID | ssj0001033888 |
Score | 2.2368526 |
Snippet | BackgroundPolymorphonuclear myeloid-derived suppressor cell (PMN-MDSC) is pathologically activated immature neutrophil that exerts immunosuppressive functions.... |
SourceID | doaj proquest bmj |
SourceType | Open Website Aggregation Database Publisher |
StartPage | A540 |
SubjectTerms | Agonists Bone marrow Flow cytometry Gastric cancer Histamine Immunotherapy Lung cancer Metastasis Neutrophils Regular and Young Investigator Award Abstracts Stem cells Tumors |
SummonAdditionalLinks | – databaseName: BMJ Open Access Journals dbid: 9YT link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV07b9swECbSFCi6FH2ibtPiho6hTT2oSKOr1EgLKAhqB3Angi8ZTmMpsJUhmbL0Z_XP9Jf0jpbhoVM3iSB4Aj9Sd0fefcfYp8TX-kRYwbWV6KDEPuNFagpurDWy9s5lgcS1Os_OLtNvczk_YNEuF-Zq2dmhWV1t0xmIoKnpRlE0CjUuVTQao4UxpJPpR-wx1SahKK7ix2x_rCLQ58rzPpIrSrIwIqci4Xz6dVbSw5A4UlCXoJieqf-fH3HQLpPn7FlvFsJ4i-MLduCbl-xJ1V98v2K_caw_D7_GUM7L7yncEODYXy9aYr6F2WQS82o6hg3Fo3fLe-9gd7sPC021OSxYel1D18LFKY_AoBr7qZ0Hcwd7Pmd9fX0Ha-JzRZ0GF9U5r06nJWhrb1d9pa9jWFJSSbvBydpG0WKTblBQoLCmLrBswLSNh1XgeHzNLidfZuUZ7ysvcBOhB8V1ljppjU9rY3Mf1yLxBYKaaGucFt661ArpdKpdnDjjpHc2im2dC2OFLfKT5A07bFDKWwY5mQSmtlnhBZpesTZxIrWWmcftWcfJgB0jDqrfORsVnJIkUwSbIrTUDjZFsA3YZwJM3Wy5OBSxY4eGdr1Q_WZTRNfkszxFzWvTqCaKMrpvdNK52glXDNjRDu694DgnUyyWuXj3f5_0nj0NyyskKB6xw2596z-gpdKZj2Ft_gULpOg5 priority: 102 providerName: BMJ Publishing Group Ltd – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbhMxELZQD4gL4lcECpoDx5p6vT_dPYYtUUFKVZFUys2yx94qpdlEyeZQTlx4LF6GJ2HG2aiVOHDhtmtZO5a_sWdmPf5GiPdpaOyJQiUt5hSg6FDIKnOVdIgub4L3RSRxHZ8XZ5fZl1k-u1fqi3PCdvTAu4k7ZuqdUJQZ7aKYJQ3TTfHZkc-9b7zy8eoe2bx7wVT8u6Io9CrLPqErSYvj63mHkmuFy8nnac0PH5gqhUyKW1z3hP1_7cfRyIyeiMe9dwjD3aieigehfSYejvvz7-fiF33r94-fQ6hn9dcMVjx86m-vlkyAC9PRSMvxZAgbTkvv5t-Dh_0hP1xZLtGBgPy6hm4JF6cyAUfW7Jv1Adwt3NE625ubW1gzrSuZNrgYn8vx6aQGi7hd9AW_jmDOd0uWm-2qT6alJtuSoMhkzV1g3oJbtgEWkerxhbgcfZrWZ7IvwCBdQoGUtAXNM7qQNQ7LoBuVhoqwTS06b1VAn6HKvc2s16l3Pg8eE41NqRwqrMqT9KU4aEnKKwElewauwaIKijwwbZ1Oc2vzItAqbXQ6EEeEg-kX0MbE2CQtDMNmGC2zh80wbAPxkQEzqx0lh2GS7NhAqmN61TH_Up2BONzDfSdYl-yR6bxUr_-HjDfiUVS6eHvxUBx06214S25M595Fjf0DEhDxKw priority: 102 providerName: Directory of Open Access Journals |
Title | 481 A CXCR4 partial agonist TFF2-MSA sensitized advanced gastric cancer to PD-1 blockade by systematically reducing PMN-MDSC accumulation, immunosuppression, and generation in bone marrow |
URI | https://jitc.bmj.com/content/11/Suppl_1/A540.full https://www.proquest.com/docview/2884672580 https://doaj.org/article/4373e684847c41f18097684d5ddfd0d9 |
Volume | 11 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3JbhNBEG2RREJcEKswBKsOHNOhPZtnDlHkTGIFpLGs2EbmNOptLCfe8CJhTlz4LH6GL6Gq05YPoFxm6emeluZVTVX18oqxD6GtZFNowaWOMUAJbMKzSGVcaa3iyhqTOBLXopNcD6LPw3i431nnP-Dqv6Ed5ZMaLCen379tz1Hhz3xGko-347XmlAac9z71c7o4JRaUA3aE5qlJ2lp4n98NvAiMytLUr_V6oD1aGzW99Vz-__yqnf1pP2NPveMIrXukn7NHdvaCPS781PhL9hvf9efnrxbkw_wmggWJBNaXozlx40K_3Q540WvBilasr8c_rIHd_D-MJGXv0KDpdgnrOXQveQMUGro7aSyoLewZn-VksoUlMb6i1YNu0eHFZS8HqfVm6nOBncCYtp3MV5uFX2eLRXKGHTmSa6oC4xmo-czC1LFAvmKD9lU_v-Y-NwNXDYyxuEwiE2tlo0rp1AaVCG2GsIdSKyOF1SbSIjYykiYIjTKxNboR6CoVSgudpc3wNTucYS9vGKTkNKhKJ5kV6JwFUgVhLGWcWFTgKghr7ARxKHeiUbqwJUxKgq0ktModbCXBVmMXBFi5uGfrKIk_2xXMl6PSq2NJhE42SSO0zTpqVERiRjOSJjamMsJkNXa8g3vfcZCSsxbEqXj78ON37IkTJ7dl8Zgdrpcb-x59l7Wqs4PmsInH7Gu_zo5aeVF8wfPFVad7U3fjAXUnrX8BT7H0vg |
linkProvider | Scholars Portal |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV07b9swECbSFGi7BH2ibtL2ho6hTVEPS6Or1HDayAhqBXAngi8ZTmMpsJUhnbr0Z_XP9JeUR8vw0KmbRBA8gR-pu-PxviPkQ2grOWSaUalj56Bwm9AsUhlVWqu4ssYknsS1mCaTq-jzPJ4fkGCXC3O9bHVfra636QxI0FS3gyAY-BqXIhiMnIXRx5PpB-ThEJlXcFF_K_fHKsz5XGna3eQKwsSPSLFIOJ2dlzk-9JEjxekSJ6Zj6v_nR-y1y_gpOerMQhhtcXxGDmz9nDwqusD3C_LbjfXn568R5PP8awS3CLjrLxcNMt9COR5zWsxGsMH76O3yhzWwi-7DQmJtDg0aX9fQNnB5RgNQTo19l8aCuoc9n7O8ubmHNfK5Op0Gl8WUFmezHKTWd6uu0tcpLDGppNm4ydreonVNsnaCPIU1doFlDaqpLaw8x-NLcjX-VOYT2lVeoCpwHhSVSWRirWxUKZ1aXrHQZg7UUGplJLPaRJrFRkbS8NAoE1ujA66rlCnNdJYOw1fksHZSXhNI0SRQlU4yy5zpxaXiYSxlnFi3PSse9sipw0F0O2cjvFMSJgJhE4iW2MEmELYe-YiAidstF4dAdmzf0KwXottsAumabJJGTvPqKKiQogzjjSY2pjLMZD1ysoN7L5inaIrxOGVv_u-T3pPHk7K4EBfn0y_H5Ilfaj5Z8YQctus7-9ZZLa1659fpXx0U6yg |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9NAEF6VIlVcEE8RKDAHjt1k_VjXPoaEqAUSRSSVwmm1L0dpGydK3EM5ceFn8Wf4JcxsHOXAiZttrXYsf7ueb3Z3vmHsQ-JLfS6s4NpKDFBin_EiNQU31hpZeueyIOI6HGUXV-nnmZwdMbnPhble1LZtlte7dAYSaKrqThR1Qo1LFXW6yDDatDLdXrvyAXuI7CUlyfzi-_SwtCIw7srz5jRXlGShV06FwvnkctqjizbppKA_QVONWv8_P-PgYQZP2OOGGkJ3h-VTduSrZ-xk2Gx-P2e_sa8_P391oTfrfUthTaBjez1fkfotTAeDmA8nXdjSmfR68cM72O_ww1xTfQ4Llm43UK9g3OcRGHRlN9p5MPdw0HTWt7f3sCFNV_RrMB6O-LA_6YG29m7ZVPs6gwUllqy2-MF2J2nxka7QUJCxpiawqMCsKg_LoPP4gl0NPk17F7ypvsBNhFEU11nqpDU-LY3NfVyKxBcIbKKtcVp461IrpNOpdnHijJPe2Si2ZS6MFbbIz5OX7LhCK68Y5EQLTGmzwgukX7E2cSK1lpnHKVrGSYudIQ6qmT1bFQKTJFMEmyK01B42RbC12EcCTK13ehyKFLLDg9VmrpoJp0iyyWd5it7XplFJMmW05-ikc6UTrmix0z3cB8NxTnQslrl4_X-v9J6djPsD9fVy9OUNexRGWshXPGXH9ebOv0XiUpt3YZj-BX_17Dc |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=481%E2%80%85A+CXCR4+partial+agonist+TFF2-MSA+sensitized+advanced+gastric+cancer+to+PD-1+blockade+by+systematically+reducing+PMN-MDSC+accumulation%2C+immunosuppression%2C+and+generation+in+bone+marrow&rft.jtitle=Journal+for+immunotherapy+of+cancer&rft.au=Qian%2C+Jin&rft.au=Ryeom%2C+Sandra&rft.au=Daugherty%2C+Bruce+L&rft.au=Lederman%2C+Seth&rft.date=2023-11-01&rft.pub=BMJ+Publishing+Group+LTD&rft.eissn=2051-1426&rft.volume=11&rft.issue=Suppl+1&rft.spage=A540&rft.epage=A540&rft_id=info:doi/10.1136%2Fjitc-2023-SITC2023.0481&rft.externalDBID=HAS_PDF_LINK |